SCHEMBL3686211

SCHEMBL3686211

COC(=O)c1sc(C(C)C)cc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 1/20 0.51
MAPT P10636 3/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 3/20 0.40
XDH P47989 2/20 0.40
LMNA P02545 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
NFKB1 P19838 1/20 0.40
GFER P55789 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
FUT7 Q11130 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CA12 O43570 5/20 0.38
CA1 P00915 5/20 0.38
CA2 P00918 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31078648 0.84 TSHR (0.44) RAF1MAPTTSHRKMT2AHSD17B10
SCHEMBL2404773 0.82 RAF1 (0.51) RAF1MAPTTSHRKMT2AHSD17B10
SCHEMBL3249150 0.82 KDM4E (0.51) RAF1MAPTTSHRKMT2AHSD17B10
SCHEMBL10265303 0.81 RAF1 (0.50) RAF1MAPTTSHRKMT2AHSD17B10
SCHEMBL31305747 0.79 RAF1 (0.49) RAF1MAPTTSHRKMT2AHSD17B10
SCHEMBL13315269 0.76 RAF1 (0.46) RAF1MAPTKMT2ALMNAGAA
SCHEMBL577650 0.76 MAPT (0.45) RAF1MAPTTSHRKMT2AHSD17B10
SCHEMBL9529269 0.76 TSHR (0.45) MAPTTSHRKMT2AHSD17B10KDM4E
SCHEMBL7670938 0.76 TSHR (0.45) MAPTTSHRKMT2AHSD17B10KDM4E
SCHEMBL31305721 0.75 RAF1 (0.45) RAF1MAPTTSHRKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1964844-B1 New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application SANOFI AVENTIS DEUTSCHLAND (DE) 2010-09-01 EP disclosed
EP-1964845-B1 New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application SANOFI AVENTIS DEUTSCHLAND (DE) 2010-08-11 EP disclosed
EP-1967523-B1 New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application SANOFI AVENTIS DEUTSCHLAND (DE) 2010-08-11 EP disclosed
US-7666848-B2 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-02-23 US disclosed
US-7666848-B2 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-02-23 US disclosed
US-7666848-B2 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-02-23 US disclosed
WO-2009138195-A2 USE OF THIOPHENE GLYCOSIDE DERIVATIVES FOR PRODUCING MEDICAMENTS FOR TREATMENT OF HYPERTENSION SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-11-19 WO disclosed
EP-1523488-B1 NOVEL THIOPHENYLGLYCOSIDE DERIVATIVES, METHODS FOR PRODUCTION THEREOF, MEDICAMENTS COMPRISING SAID COMPOUNDS AND USE THEREOF SANOFI AVENTIS DEUTSCHLAND (DE) 2008-11-12 EP disclosed
EP-1967523-A1 New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application Sanofi-Aventis Deutschland GmbH (DE) 2008-09-10 EP disclosed
EP-1964845-A1 New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application Sanofi-Aventis Deutschland GmbH (DE) 2008-09-03 EP disclosed
CN-101240000-A Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof SANOFI AVENTIS DEUTSCHLAND (DE) 2008-08-13 CN disclosed
CN-100384863-C Novel thienyl glycoside derivatives, method for the production thereof, medicaments containing said compounds and the use thereof AVENTIS PHARMA GMBH (DE) 2008-04-30 CN disclosed
US-20060293252-A1 Novel Thiophene Glycoside Derivatives, Processes for The Preparation, Medicaments Comprising These Compounds, and The Use Thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-12-28 US disclosed
US-7101856-B2 Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2006-09-05 US disclosed
CN-1668628-A Novel thienyl glycoside derivatives, method for the production thereof, medicaments containing said compounds and the use thereof AVENTIS PHARMA GMBH (DE) 2005-09-14 CN disclosed
US-20040138143-A1 Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2004-07-15 US disclosed
EP-0249236-B1 N-1H-TETRAZOL-5-YL-(5-RING)-CARBOXAMIDE-DERIVATIVES, A PROCESS FOR THEIR MANUFACTURE, AND THE USE THEREOF WARNER-LAMBERT COMPANY (US) 1991-04-24 EP disclosed
US-4824958-A Process for the preparation of n-1H-tetrazol-5-yl-2-pyrrole carboxamides WARNER-LAMBERT COMPANY (US) 1989-04-25 US disclosed
US-4748183-A N-1H-tetrazol-5-yl-2-thiophene carboxamides, N-1H-tetrazol-5-yl-2-pyrrole carboxamides, N-1H-tetrazol-5-yl-2-furan carboxamides, and anti-allergic and anti-inflammatory use thereof WARNER-LAMBERT COMPANY (US) 1988-05-31 US disclosed
EP-0249236-A1 N-1H-Tetrazol-5-yl-(5-Ring)-carboxamide-derivatives, a process for their manufacture, and the use thereof WARNER-LAMBERT COMPANY (US) 1987-12-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138143-A1 Novel thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof SLC5A1, SLC5A2, UGGT1 RAF1 2976/4885MAPT 4430/4885TSHR 1537/4885
US-20060293252-A1 Novel Thiophene Glycoside Derivatives, Processes for The Preparation, Medicaments Comprising These Compounds, and The Use Thereof SLC5A2, SLC5A1, DPP4 RAF1 3173/4885MAPT 4345/4885TSHR 1298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.